Evaluation of an algorithmic approach in comparison with the illumigene assay for laboratory diagnosis of clostridium difficile infection

Journal of Clinical Microbiology

Volumn 51, Issue 4, 2013, Pages 1152-1157

  Walkty, A ^a,b,c   Lagace Wiens P R S ^a,b   Manickam, K ^a,b   Adam, H ^a,b   Pieroni, P ^a   Hoban, D ^a,b   Karlowsky, J A ^a,b   Alfa, M ^a,b  

^a Diagnostic Services of Manitoba Inc   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; BACTERIUM DETECTION; CELL CYTOTOXICITY ASSAY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CULTURE TECHNIQUE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FECES ANALYSIS; GLUTAMATE DEHYDROGENASE ANTIGEN SCREEN; HUMAN; HUMAN CELL; ILLUMIGENE ASSAY; INTERMETHOD COMPARISON; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TOXIGENIC CULTURE; TOXIN AB ANTIGEN TESTING; TURNAROUND TIME;

ALGORITHMS; BACTERIAL TOXINS; CLINICAL LABORATORY TECHNIQUES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECES; FEMALE; GLUTAMATE DEHYDROGENASE; HUMANS; MALE; MANITOBA; SENSITIVITY AND SPECIFICITY;

CLOSTRIDIUM DIFFICILE;

EID: 84875841211     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03203-12     Document Type: Article

References (20)

1. Bartlett JG, Gerding DN. 2008. Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis. 46:S12-S18.
2. Kelly CP, LaMont JT. 2008. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359:2932-2940.
3. Poutanen SM, Simor AE. 2004. Clostridium difficile-associated diarrhea in adults. Can. Med. Assoc. J. 171:51-58.
4. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, Mulvey M, the Canadian Nosocomial Infection Surveillance Program. 2009. Heath careassociated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program study. Clin. Infect. Dis. 48:568-576.
5. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
6. Crobach MJT, Dekkers OM, Wilcox MH, Kuijper EJ. 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficileinfection (CDI). Clin. Microbiol. Infect. 15:1053-1066.
7. Larson AM, Fung AM, Fang FC. 2010. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J. Clin. Microbiol. 48:124-130.
8. Swindells J, Brenwald N, Reading N, Oppenheim B. 2010. Evaluation of diagnostic tests for Clostridium difficile infection. J. Clin. Microbiol. 48: 606-608.
9. Dubberke ER, Han Z, Bobo L, Hink T, Lawrence B, Copper S, Hoppe-Bauer J, Burnham CAD, Dunne WM, Jr. 2011. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J. Clin. Microbiol. 49:2887-2893.
10. Lalande V, Barrault L, Wadel S, Eckert C, Petit JC, Barbut F. 2011. Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. J. Clin. Microbiol. 49:2714-2716.
11. Norén T, Alriksson I, Andersson J, Akerlund T, Unemo M. 2011. Rapid and sensitive loop-mediated isothermal amplification test for Clostridium difficile detection challenges cytotoxin B cell test and culture as gold standard. J. Clin. Microbiol. 49:710-711.
12. Techlab Inc. 2009. C. Diff Quik Chek package insert. Techlab Inc., Blacksburg, VA.
13. Techlab Inc. 2009. Tox A/B Quik Chek package insert. Techlab Inc., Blacksburg, VA.
14. Trinity Biotech Company. 2011. Bartels cytotoxicity assay for Clostridium difficile, toxin kit insert. Trinity Biotech Company, Carlsbad, CA.
15. Meridian Bioscience. 2011. Illumigene package insert. Meridian Bioscience, Cincinnati, OH.
16. Alfa M, Swan B, VanDekerkhove B, Pang P, Harding GKM. 2002. The diagnosis of Clostridium difficile-associated diarrhea: Comparison of Triage ® C. difficile panel, EIA for tox A/B and cytotoxin assays. Diagn. Microbiol. Infect. Dis. 43:257-263.
17. Pancholi P, Kelly C, Raczkowski M, Balada-Llasat JM. 2012. Detection of toxigenic Clostridium difficile: Comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. J. Clin. Microbiol. 50:1331-1335.
18. Boyanton BL, Jr, Sural P, Loomis CR, Pesta C, Gonzalez-Krellwitz L, Robinson-Dunn B, Riska P. 2012. Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. J. Clin. Microbiol. 50:640-645.
19. Aspinall ST, Hutchisnson DN. 1992. New selective medium for isolating Clostridium difficile from faeces. J. Clin. Pathol. 45:812-814.
20. Gyorke CE, Wang S, Leslie JL, Cohen SH, Solnick JV, Polage CR. 2013. Evaluation of Clostridium difficile fecal load and limit of detection during a prospective comparison of two molecular tests, the illumigene C. difficile and Xpert C. difficile/Epi tests. J. Clin. Microbiol. 51:278-280.